Alterity Therapeutics Limited (ATH.AX)
AUD 0.01
(11.11%)
AUD 0.01
(11.11%)
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 | 3.8 Million AUD | 4.78% |
| 2023 | 3.63 Million AUD | -23.69% |
| 2022 | 4.75 Million AUD | 19.58% |
| 2021 | 3.97 Million AUD | 3639.7% |
| 2020 | -112.42 Thousand AUD | -242.6% |
| 2019 | 78.84 Thousand AUD | -56.05% |
| 2018 | 179.37 Thousand AUD | 61.5% |
| 2017 | 111.06 Thousand AUD | -7.33% |
| 2016 | 119.84 Thousand AUD | 248.96% |
| 2015 | -80.45 Thousand AUD | -100.98% |
| 2014 | 8.2 Million AUD | 82.89% |
| 2013 | 4.48 Million AUD | 2304.6% |
| 2012 | 186.66 Thousand AUD | 176.78% |
| 2011 | -243.1 Thousand AUD | -213.07% |
| 2010 | 215 Thousand AUD | -49.79% |
| 2009 | 428.19 Thousand AUD | -12.97% |
| 2008 | 491.99 Thousand AUD | -2.97% |
| 2007 | 507.04 Thousand AUD | -33.5% |
| 2006 | 762.48 Thousand AUD | -71.14% |
| 2005 | 2.64 Million AUD | 14.53% |
| 2004 | 2.3 Million AUD | 27.39% |
| 2003 | 1.81 Million AUD | 127.98% |
| 2002 | 794.39 Thousand AUD | 53.9% |
| 2001 | 516.18 Thousand AUD | 555.4% |
| 2000 | 78.75 Thousand AUD | 0.0% |
| 1999 | - AUD | 0.0% |
| 1998 | - AUD | 0.0% |
| Year | Gross Profit | Gross Profit Growth |
|---|---|---|
| 2024 Q4 | 2.04 Million AUD | 0.0% |
| 2024 FY | -147.52 Thousand AUD | -104.06% |
| 2024 Q2 | 1.82 Million AUD | 0.0% |
| 2023 FY | 3.63 Million AUD | -23.69% |
| 2023 Q4 | 1.47 Million AUD | 0.0% |
| 2023 Q2 | 2.33 Million AUD | 0.0% |
| 2022 Q4 | 2.74 Million AUD | 0.0% |
| 2022 Q2 | 2.32 Million AUD | 0.0% |
| 2022 FY | 4.75 Million AUD | 19.58% |
| 2021 FY | 3.97 Million AUD | 3639.7% |
| 2021 Q4 | 2.41 Million AUD | 0.0% |
| 2021 Q2 | 1.84 Million AUD | 0.0% |
| 2020 Q1 | 876.47 Thousand AUD | -65.08% |
| 2020 FY | -112.42 Thousand AUD | -242.6% |
| 2020 Q2 | 1.79 Million AUD | 105.14% |
| 2020 Q3 | -1.05 Million AUD | -158.56% |
| 2020 Q4 | -1.91 Million AUD | -81.43% |
| 2019 Q3 | 1.14 Million AUD | -51.25% |
| 2019 Q1 | 1.17 Million AUD | -23.34% |
| 2019 Q4 | 2.5 Million AUD | 119.64% |
| 2019 FY | 78.84 Thousand AUD | -56.05% |
| 2019 Q2 | 2.34 Million AUD | 100.0% |
| 2018 Q3 | 764.36 Thousand AUD | -44.31% |
| 2018 Q2 | 1.37 Million AUD | 100.0% |
| 2018 FY | 179.37 Thousand AUD | 61.5% |
| 2018 Q4 | 1.52 Million AUD | 100.0% |
| 2018 Q1 | 686.23 Thousand AUD | -38.62% |
| 2017 Q1 | 897.6 Thousand AUD | -53.2% |
| 2017 Q3 | 558.98 Thousand AUD | -68.86% |
| 2017 Q2 | 1.79 Million AUD | 100.0% |
| 2017 FY | 111.06 Thousand AUD | -7.33% |
| 2017 Q4 | 1.11 Million AUD | 100.0% |
| 2016 Q4 | 1.91 Million AUD | 100.0% |
| 2016 Q2 | 2.73 Million AUD | 100.0% |
| 2016 Q3 | 958.92 Thousand AUD | -64.96% |
| 2016 Q1 | 1.36 Million AUD | -53.13% |
| 2016 FY | 119.84 Thousand AUD | 248.96% |
| 2015 FY | -80.45 Thousand AUD | -100.98% |
| 2015 Q2 | 3.31 Million AUD | 100.0% |
| 2015 Q3 | 1.45 Million AUD | -56.01% |
| 2015 Q4 | 2.91 Million AUD | 100.0% |
| 2015 Q1 | 1.65 Million AUD | -73.66% |
| 2014 Q2 | 1.43 Million AUD | 100.0% |
| 2014 FY | 8.2 Million AUD | 82.89% |
| 2014 Q3 | 3.14 Million AUD | 119.51% |
| 2014 Q1 | 717.22 Thousand AUD | -67.16% |
| 2014 Q4 | 6.29 Million AUD | 100.0% |
| 2013 Q3 | 1.09 Million AUD | -49.44% |
| 2013 Q4 | 2.18 Million AUD | 100.0% |
| 2013 Q1 | 1.08 Million AUD | 0.0% |
| 2013 FY | 4.48 Million AUD | 2304.6% |
| 2013 Q2 | 2.16 Million AUD | 100.0% |
| 2012 FY | 186.66 Thousand AUD | 176.78% |
| 2011 FY | -243.1 Thousand AUD | -213.07% |
| 2010 FY | 215 Thousand AUD | -49.79% |
| 2009 FY | 428.19 Thousand AUD | -12.97% |
| 2008 Q1 | 127 Thousand AUD | -5.83% |
| 2008 FY | 491.99 Thousand AUD | -2.97% |
| 2008 Q4 | 119.15 Thousand AUD | 0.41% |
| 2008 Q3 | 118.66 Thousand AUD | -6.53% |
| 2008 Q2 | 126.96 Thousand AUD | -0.04% |
| 2007 FY | 507.04 Thousand AUD | -33.5% |
| 2007 Q4 | 134.86 Thousand AUD | -0.25% |
| 2007 Q3 | 135.2 Thousand AUD | 14.02% |
| 2007 Q2 | 118.58 Thousand AUD | 0.23% |
| 2007 Q1 | 118.3 Thousand AUD | -37.88% |
| 2006 Q3 | 190.67 Thousand AUD | -12.25% |
| 2006 Q2 | 217.31 Thousand AUD | 0.01% |
| 2006 Q1 | 217.29 Thousand AUD | -65.01% |
| 2006 FY | 762.48 Thousand AUD | -71.14% |
| 2006 Q4 | 190.44 Thousand AUD | -0.12% |
| 2005 Q3 | 637 Thousand AUD | -7.02% |
| 2005 Q4 | 621.08 Thousand AUD | -2.5% |
| 2005 FY | 2.64 Million AUD | 14.53% |
| 2005 Q2 | 685.06 Thousand AUD | 0.1% |
| 2005 Q1 | 684.35 Thousand AUD | 13.98% |
| 2004 Q4 | 600.43 Thousand AUD | -0.66% |
| 2004 Q1 | 561.87 Thousand AUD | -29.88% |
| 2004 FY | 2.3 Million AUD | 27.39% |
| 2004 Q3 | 604.41 Thousand AUD | 7.61% |
| 2004 Q2 | 561.68 Thousand AUD | -0.03% |
| 2003 Q4 | 801.31 Thousand AUD | 39.57% |
| 2003 Q1 | 242.4 Thousand AUD | 0.0% |
| 2003 Q2 | 263.42 Thousand AUD | 8.67% |
| 2003 FY | 1.81 Million AUD | 127.98% |
| 2003 Q3 | 574.13 Thousand AUD | 117.96% |
| 2002 FY | 794.39 Thousand AUD | 53.9% |
| 2001 FY | 516.18 Thousand AUD | 555.4% |
| 2000 FY | 78.75 Thousand AUD | 0.0% |
| 1999 FY | - AUD | 0.0% |
| 1998 FY | - AUD | 0.0% |
| Name | Gross Profit | Gross Profit Difference |
|---|---|---|
| AdAlta Limited | 1.5 Million AUD | -152.334% |
| Acrux Limited | -1.28 Million AUD | 396.338% |
| Actinogen Medical Limited | 9.93 Million AUD | 61.688% |
| AnteoTech Limited | 460.39 Thousand AUD | -726.457% |
| Argenica Therapeutics Limited | 2.59 Million AUD | -46.462% |
| Arovella Therapeutics Limited | -25.97 Thousand AUD | 14746.372% |
| Anatara Lifesciences Ltd | -748.91 Thousand AUD | 608.069% |
| Amplia Therapeutics Limited | 4.01 Million AUD | 5.13% |
| Avecho Biotechnology Limited | -43.79 Thousand AUD | 8788.163% |
| Bio-Gene Technology Limited | -301.44 Thousand AUD | 1362.23% |
| Biome Australia Limited | 7.66 Million AUD | 50.389% |
| Biotron Limited | -40.49 Thousand AUD | 9495.479% |
| Botanix Pharmaceuticals Limited | -6.55 Million AUD | 158.078% |
| BTC Health Limited | 16.36 Thousand AUD | -23157.83% |
| Chimeric Therapeutics Limited | 7.45 Million AUD | 48.952% |
| CSL Limited | 15.28 Billion AUD | 99.975% |
| Clarity Pharmaceuticals Ltd | 11.5 Million AUD | 66.932% |
| Clinuvel Pharmaceuticals Limited | 78.09 Million AUD | 95.128% |
| Cynata Therapeutics Limited | 2.31 Million AUD | -64.316% |
| Dimerix Limited | 583.47 Thousand AUD | -552.121% |
| EZZ Life Science Holdings Limited | 50.94 Million AUD | 92.531% |
| Hexima Limited | - AUD | -Infinity% |
| Island Pharmaceuticals Limited | 1.25 Million AUD | -204.015% |
| Immuron Limited | 3.33 Million AUD | -14.031% |
| Immutep Limited | 1.44 Million AUD | -163.52% |
| Imugene Limited | -5.83 Million AUD | 165.155% |
| Invex Therapeutics Ltd | 1.21 Million AUD | -213.876% |
| Memphasys Limited | 1606.00 AUD | -236822.852% |
| Nanollose Limited | -348.95 Thousand AUD | 1190.402% |
| Neuren Pharmaceuticals Limited | 205.17 Million AUD | 98.145% |
| Noxopharm Limited | -534.81 Thousand AUD | 811.463% |
| NeuroScientific Biopharmaceuticals Limited | -91.33 Thousand AUD | 4265.87% |
| Nyrada Inc. | -5164.07 AUD | 73781.825% |
| Orthocell Limited | 3.68 Million AUD | -3.16% |
| PharmAust Limited | -1641.00 AUD | 231969.653% |
| Patrys Limited | 1.39 Million AUD | -172.922% |
| Paradigm Biopharmaceuticals Limited | 56.81 Thousand AUD | -6597.495% |
| Proteomics International Laboratories Limited | -1.12 Million AUD | 438.766% |
| Prescient Therapeutics Limited | 3.71 Million AUD | -2.495% |
| PYC Therapeutics Limited | 22.05 Million AUD | 82.751% |
| Race Oncology Limited | 1.38 Million AUD | -173.756% |
| Radiopharm Theranostics Limited | -21.3 Million AUD | 117.857% |
| Recce Pharmaceuticals Ltd | -366.76 Thousand AUD | 1137.435% |
| Starpharma Holdings Limited | 7.65 Million AUD | 50.307% |
| Telix Pharmaceuticals Limited | 308.5 Million AUD | 98.767% |
| Tissue Repair Ltd | 150.51 Thousand AUD | -2428.042% |
| Zelira Therapeutics Limited | 10.28 Thousand AUD | -36899.037% |